Humana faces significant earnings headwinds due to CMS reforms, star rating downgrades, and potential Medicaid clawbacks.

The changes would limit how insurers add patient diagnoses that trigger lucrative extra payments.

Humana (HUM) backs reforms on extra Medicare Advantage payments from home visits and chart review. Read more here.

Humana has told congressional staffers that it will support moves that would curtail billing practices worth billions in ...

Bernstein SocGen Group analysts reiterated an ‘Outperform’ rating on Humana Inc. (NYSE:HUM) and a $313 price target. The ...

The tech-heavy Nasdaq Composite rallied more than 9% this month. Information technology stocks are the top-performing sector ...

Humana (HUM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Humana, (NYSE:HUM) listed on the NYSE and a constituent of the Russell 1000, operates within the health care sector.

Major indices were little changed early on Wednesday as market participants awaited the release of minutes from the Federal ...

This handy guide will help you understand some of the jargon in corporate earnings reports and why it is important for ...

In Medicare Advantage, UnitedHealth holds a firm advantage, having increased its market share from 25% in 2017 to 29% in 2023. For comparison, Humana (NYSE: HUM) holds 18% market share in both periods ...

AutoZone and Okta are set to report on Tuesday ... Wednesday night brings earnings from two heavy hitters, Nvidia and Salesforce. Nvidia's stock has been "in no man's land," according to Cramer.